RevolKa
Sendai, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $710M
Overview
RevolKa uses AI-driven protein engineering to accelerate the development of novel biopharmaceuticals and industrial enzymes.
Rare Diseases
Technology Platform
aiProtein® is a proprietary protein engineering platform that integrates artificial intelligence (using custom models and Low-N learning) with laboratory-based directed evolution to design high-performance proteins from limited experimental data.
Opportunities
Significant opportunity to leverage its validated AI-protein platform for broad partnership deals in antibody and enzyme engineering, and to advance its proprietary rare disease therapeutics with government grant support.
Risk Factors
As a young, platform-focused company, RevolKa faces risks including dependence on key partnerships for revenue, technological competition from global AI-biotech firms, and the inherent challenges of translating platform success into proprietary clinical assets.
Competitive Landscape
Competes with global AI-driven protein design companies like Absci, Generate Biomedicines, and LabGenius. RevolKa differentiates through its specific hybrid AI/wet-lab evolution approach, strong academic roots from Tohoku University, and early validation with major Japanese pharma partners.